ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,030.75
-0.07%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Harpoon Therapeutics Inc (HARP)

  7. Harpoon Therapeutics Inc (HARP) Noticias

HARP

Harpoon Therapeutics (HARP)

Harpoon Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:HARP
FechaHoraFuenteTítuloSímboloCompañía
11/03/202416:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202408:55Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202408:46Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202407:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HARPHarpoon Therapeutics Inc
28/02/202406:37Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:HARPHarpoon Therapeutics Inc
08/02/202406:00Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:HARPHarpoon Therapeutics Inc
06/02/202415:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HARPHarpoon Therapeutics Inc
29/01/202415:52Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:HARPHarpoon Therapeutics Inc
10/01/202414:07PR Newswire (US)Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmNASDAQ:HARPHarpoon Therapeutics Inc
09/01/202405:12IH Market NewsWall Street Highlights: HPE and Juniper Networks in Negotiations, Elliott Invests $1 Billion in Match Group, and MoreNASDAQ:HARPHarpoon Therapeutics Inc
08/01/202406:30Business WireMerck to Acquire Harpoon Therapeutics, Further Diversifying Oncology PipelineNASDAQ:HARPHarpoon Therapeutics Inc
05/01/202416:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HARPHarpoon Therapeutics Inc
26/12/202306:30GlobeNewswire Inc.Harpoon Therapeutics Strengthens Leadership TeamNASDAQ:HARPHarpoon Therapeutics Inc
22/12/202315:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:HARPHarpoon Therapeutics Inc
19/12/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HARPHarpoon Therapeutics Inc
19/12/202306:30GlobeNewswire Inc.Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers SymposiumNASDAQ:HARPHarpoon Therapeutics Inc
11/12/202319:15GlobeNewswire Inc.Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)NASDAQ:HARPHarpoon Therapeutics Inc
08/12/202315:08Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:HARPHarpoon Therapeutics Inc
24/11/202313:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HARPHarpoon Therapeutics Inc
09/11/202315:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HARPHarpoon Therapeutics Inc
09/11/202315:01GlobeNewswire Inc.Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:HARPHarpoon Therapeutics Inc
03/11/202315:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HARPHarpoon Therapeutics Inc
02/11/202308:15GlobeNewswire Inc.Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:HARPHarpoon Therapeutics Inc
23/10/202306:17GlobeNewswire Inc.Harpoon Therapeutics Announces Up to $150 Million Private PlacementNASDAQ:HARPHarpoon Therapeutics Inc
21/10/202310:31GlobeNewswire Inc.Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023NASDAQ:HARPHarpoon Therapeutics Inc
16/10/202315:05GlobeNewswire Inc.Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023NASDAQ:HARPHarpoon Therapeutics Inc
09/10/202315:17GlobeNewswire Inc.Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023NASDAQ:HARPHarpoon Therapeutics Inc
28/09/202302:00GlobeNewswire Inc.Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual MeetingNASDAQ:HARPHarpoon Therapeutics Inc
15/09/202306:15GlobeNewswire Inc.Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination CohortNASDAQ:HARPHarpoon Therapeutics Inc
13/09/202316:12Dow Jones NewsHarpoon Shares Drop 7.3% as AbbVie Declines License OptionNASDAQ:HARPHarpoon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HARP

Su Consulta Reciente

NYSE
ISOS.WS
Isos Acquisition
LSE
INDU
Wt Indu Metals
BIT
F17265
Vontobel Financial Produ...
USOTC
GMOFF
GMO Financial Gate (PK)
LSE
CGH
Chaarat Gold
NASDAQ
SKOR
FlexShares Credit Scored...
LSE
90MG
Newday Fmi 24 S
USOTC
BNZIF
Banco Invex SA Instituci... (CE)
COIN
X2GBP
COIN
GBEXUST
Globiance Exchange Token
EU
INSTN
SPDR STN Inav
USOTC
CEOA
CEO America (CE)
LSE
TBLS
Tinybuild
NYSE
CARS
Cars com
DOWI
DJCIFCT
DJ Commodity Index Feede...
BIT
P1PKR2
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados